---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-001454"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:24:29.358433+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corvus Q4 net loss $6.7M; soquelitinib Orphan Drug; Phase 3 PTCL trial on track

## Summary
- Net loss $6.7M in Q4 2023 vs $9.8M Q4 2022; cash $27.1M at Dec 31, 2023.
- Soquelitinib Phase 1/1b: 7 of 21 evaluable PTCL patients had objective responses (4 CR, 3 PR).
- FDA granted Orphan Drug Designation for soquelitinib in T cell lymphoma (Feb 2024).
- Registrational Phase 3 PTCL trial expected to initiate Q3 2024; Phase 1 atopic dermatitis trial Q2 2024.
- Appointed Jeffrey Arcara as Chief Business Officer to lead corporate strategy and business development.

## SEC filing metadata
- accession: 0001171843-24-001454
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184324001454/0001171843-24-001454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184324001454/f8k_031924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-001454
- JSON: https://secwatch.observer/filing/0001171843-24-001454.json
- Plain text: https://secwatch.observer/filing/0001171843-24-001454.txt

## Key facts
- Earnings Releases
  Corvus Pharmaceuticals, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: Corvus Pharmaceuticals, Inc. issued a press release regarding, among other matters, its financial results for the fourth quarter and full year ended December 31, 2023 and its financial position as of December 31, 2023, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000117184324001454/0001171843-24-001454-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.